Evidence map›Paper›PMID 30718253›Full record

ArticleAntimicrobial agents and chemotherapy2019

A FASII Inhibitor Prevents Staphylococcal Evasion of Daptomycin by Inhibiting Phospholipid Decoy Production.

Carmen J E Pee, Vera Pader, Elizabeth V K Ledger, Andrew M Edwards

Open access · hybridAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. RexAB is essential for the mutagenic repair ofAntimicrobial agents and chemotherapy · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Carmen J E Pee *MRC Centre for Molecular Bacteriology and Infection, Imperial College London, London, United Kingdom.
Vera Pader *MRC Centre for Molecular Bacteriology and Infection, Imperial College London, London, United Kingdom.ORCID 0000-0002-9684-2338
Elizabeth V K Ledger *MRC Centre for Molecular Bacteriology and Infection, Imperial College London, London, United Kingdom.ORCID 0000-0003-1126-6640
Andrew M EdwardsMRC Centre for Molecular Bacteriology and Infection, Imperial College London, London, United Kingdom a.edwards@imperial.ac.uk.ORCID 0000-0002-7173-7355
Imperial College London · GB

Funding

Medical Research Council MR/P028225/1Wellcome TrustWellcome Trust 203812/Z/16/Z
6 · The paper itself

Abstract

Daptomycin is a treatment of last resort for serious infections caused by drug-resistant Gram-positive pathogens, such as methicillin-resistant

Indexed as

Anti-Bacterial AgentsBenzofuransDaptomycinDrug CombinationsFatty AcidsHumansMethicillin-Resistant Staphylococcus aureusMicrobial Sensitivity TestsPhospholipidsPyronesStaphylococcal InfectionsAnti-Bacterial AgentsAPI 1252BenzofuransDaptomycinDrug CombinationsFatty AcidsPhospholipidsPyronesAFN-1252antibiotic resistancedaptomycinexperimental therapeuticsphospholipidsStaphylococcus aureus

Identifiers

PMID30718253
PMCPMC6496159
OpenAlexW2950077073

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.